PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-0.26
Both firms show negative OCF/share. Martin Whitman would suspect an industry-wide challenge or high growth burn rates.
-0.26
Both firms show negative FCF/share. Martin Whitman might see an industry-wide capital intensity challenge.
-0.12%
Negative ratio while TRAW is 0.00%. Joel Greenblatt would question whether the firm’s OCF is negative or capex is abnormally large.
1.13
Similar ratio to TRAW's 1.04. Walter Schloss might see both operating with comparable cash conversion.
-615.00%
Both show negative ratio. Martin Whitman would question if the industry struggles with unprofitable or upfront costs.